Model Title Journal Year
Bowel Benefits, harms and costs of potential age-extensions to the National Bowel Cancer Screening Program in Australia: Impact of inviting people aged 40-49 years and 75-84 years Cancer Epidemiology, Biomarkers and Prevention 2018
Bowel Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia International Journal of Cancer 2018
Cervix Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: example from New Zealand Vaccine 2018

The projected timeframe until cervical cancer elimination in Australia

The Lancet Public Health 2018

Australia on-track to be the first country to achieve cervical cancer elimination

HPV World 2018
Cervix HPV and Oropharyngeal Cancer among Indigenous Australians: Study Protocol JMIR Resarch Protocols 2018
Cervix Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia PLoS One 2018
Lung Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia Journal of Thoracic Oncology 2018
Bowel Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study The Lancet Public Health 2017
Cervix Cost-effectiveness estimates: the need for complete reporting Authors' reply The Lancet Public Health 2017
Cervix Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program The Lancet Public Health 2017
Cervix Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia PLoS One 2017
Cervix How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country International Journal of Cancer 2017
Cervix Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries International Journal of Cancer 2016
Cervix Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models The Lancet Public Health 2016
Cervix Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand PLoS ONE 2016
Cervix Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use BMC Health Services Research 2016
Cervix Impact of+A15 HPV sample self-collection for underscreened women in the renewed National Cervical Screening Program Medical Journal of Australia 2016
Cervix Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis The Lancet Public Health 2016
Cervix The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds Health Technology Assessment 2014
Cervix Testing previous model predictions against new data on human papillomavirus vaccination program outcomes BMC Research Notes 2014
Cervix Incremental benefits of male HPV vaccination: Accounting for inequality in population uptake PLoS One 2014
Cervix Cost-effectiveness of HPV test of cure following treatment for Cervical Intraepithelial Neoplasia: Results from the NHS Sentinel Sites Study BMJ 2012
Cervix A revision of sexual mixing matrices in models of sexually transmitted infection Statistics in Medicine 2012
Cervix Expenditure and resource utilisation for cervical screening in Australia BMC Health Services Research 2012
Cervix The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia Vaccine 2011
Cervix Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study BMC Cancer 2011
Cervix MAVARIC a comparison of automation-assisted and manual cervical screening: a randomised controlled trial Health Technology Assessment 2011
Cervix Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies Vaccine 2011
Cervix Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years BMC Public Health 2010
Breast A microsimulation model of the BreastScreen Australia program 18th World IMACS Congress and MODSIM09 International Congress on Modelling and Simulation 2009
Cervix The predicted impact of vaccination on human papillomavirus infections in Australia International Journal of Cancer 2008

Model Title Report Country Year

National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting

MSAC Application No. 1276 Australia 2014

Evaluation of Sentinel Sites for HPV Triage and Test of Cure

Report to NHS Cancer Screening Programmes England 2011
Cervix Cost-effectiveness modelling beyond MAVARIC study end-points Health Technology Assessment England 2011

Human Papillomavirus Triage Test For Women With Possible or Definite Low-Grade Squamous Intraepithelial Lesions

Report for the Medical Services Advisory Committee (MSAC Reference 39) Australia 2009
Cervix Automation Assisted and Liquid Based Cytology for Cervical Cancer Screening Report for the Medical Services Advisory Committee (MSAC Assessment 1122) Australia 2009